Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparative Proteomics Unveils LRRFIP1 as a New Player in the DAPK1 Interactome of Neurons Exposed to Oxygen and Glucose Deprivation

  • Gregorio-Rocasolano Barbany, Núria de|||0000-0001-5248-7525
  • Guirao, Verónica
  • Ponce, Jovita
  • Melià Sorolla, Marc|||0000-0002-4425-1077
  • Aliena-Valero, Alicia
  • García Serran, Alexia|||0000-0003-1630-1302
  • Salom, Juan B.|||0000-0002-4162-6101
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Martí-Sistac, Octavi
  • Gasull Dalmau, Teresa|||0000-0002-9321-1741
Death-associated protein kinase 1 (DAPK1) is a pleiotropic hub of a number of networked distributed intracellular processes. Among them, DAPK1 is known to interact with the excitotoxicity driver NMDA receptor (NMDAR), and in sudden pathophysiological conditions of the brain, e.g., stroke, several lines of evidence link DAPK1 with the transduction of glutamate-induced events that determine neuronal fate. In turn, DAPK1 expression and activity are known to be affected by the redox status of the cell. To delineate specific and differential neuronal DAPK1 interactors in stroke-like conditions in vitro, we exposed primary cultures of rat cortical neurons to oxygen/glucose deprivation (OGD), a condition that increases reactive oxygen species (ROS) and lipid peroxides. OGD or control samples were co-immunoprecipitated separately, trypsin-digested, and proteins in the interactome identified by high-resolution LC-MS/MS. Data were processed and curated using bioinformatics tools. OGD increased total DAPK1 protein levels, cleavage into shorter isoforms, and dephosphorylation to render the active DAPK1 form. The DAPK1 interactome comprises some 600 proteins, mostly involving binding, catalytic and structural molecular functions. OGD up-regulated 190 and down-regulated 192 candidate DAPK1-interacting proteins. Some differentially up-regulated interactors related to NMDAR were validated by WB. In addition, a novel differential DAPK1 partner, LRRFIP1, was further confirmed by reverse Co-IP. Furthermore, LRRFIP1 levels were increased by pro-oxidant conditions such as ODG or the ferroptosis inducer erastin. The present study identifies novel partners of DAPK1, such as LRRFIP1, which are suitable as targets for neuroprotection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Article targeting pro-oxidant iron with deferoxamine as a treatment for ischemic stroke, safety and optimal dose selection in a randomized clinical trial

  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Gregorio-Rocasolano Barbany, Núria de|||0000-0001-5248-7525
  • Pérez de la Ossa, Natalia|||0000-0002-6063-211X
  • Reverté, Silvia|||0000-0002-2052-9978
  • Costa Pages, Joan
  • Giner, Pilar
  • Silva, Yolanda
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Rodríguez-Yáñez, Manuel
  • Nombela, Florentino
  • Campos, Francisco|||0000-0001-8665-1039
  • Serena, Joaquín|||0000-0002-4478-7744
  • Vivancos, José
  • Martí-Sistac, Octavi
  • Cortés, Jordi|||0000-0002-3764-0795
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Gasull Dalmau, Teresa|||0000-0002-9321-1741
A role of iron as a target to prevent stroke-induced neurodegeneration has been recently revisited due to new evidence showing that ferroptosis inhibitors are protective in experimental ischemic stroke and might be therapeutic in other neurodegenerative brain pathologies. Ferroptosis is a new form of programmed cell death attributed to an overwhelming lipidic peroxidation due to excessive free iron and reactive oxygen species (ROS). This study aims to evaluate the safety and tolerability and to explore the therapeutic efficacy of the iron chelator and antioxidant deferoxamine mesylate (DFO) in ischemic stroke patients. Administration of placebo or a single DFO bolus followed by a 72 h continuous infusion of three escalating doses was initiated during the tPA infusion, and the impact on blood transferrin iron was determined. Primary endpoint was safety and tolerability, and secondary endpoint was good clinical outcome (clinicalTrials.gov NCT00777140). DFO was found safe as adverse effects were not different between placebo and DFO arms. DFO (40-60 mg/Kg/day) reduced the iron saturation of blood transferrin. A trend to efficacy was observed in patients with moderate-severe ischemic stroke (NIHSS.